Cargando…

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice

Influenza, a respiratory disease mainly caused by influenza A and B, viruses of the Orthomyxoviridae, is still a burden on our society’s health and economic system. Influenza A viruses (IAV) circulate in mammalian and avian populations, causing seasonal outbreaks with high numbers of cases. Due to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langenmayer, Martin C., Luelf-Averhoff, Anna-Theresa, Marr, Lisa, Jany, Sylvia, Freudenstein, Astrid, Adam-Neumair, Silvia, Tscherne, Alina, Fux, Robert, Rojas, Juan J., Blutke, Andreas, Sutter, Gerd, Volz, Asisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383309/ https://www.ncbi.nlm.nih.gov/pubmed/37513714 http://dx.doi.org/10.3390/pathogens12070867

Ejemplares similares

Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2023)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
por: Veit, Svenja, et al.
Publicado: (2018)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
por: Volz, Asisa, et al.
Publicado: (2018)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
por: Tscherne, Alina, et al.
Publicado: (2021)

Development of Eczema Vaccinatum in Atopic Mouse Models and Efficacy of MVA Vaccination against Lethal Poxviral Infection
por: Knitlova, Jarmila, et al.
Publicado: (2014)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2019)

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
por: Do, Kim Thi Hoang, et al.
Publicado: (2023)

Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA
por: Orubu, Toritse, et al.
Publicado: (2012)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Proliferative Kidney Disease and Proliferative Darkening Syndrome are Linked with Brown Trout (Salmo trutta fario) Mortalities in the Pre-Alpine Isar River
por: Arndt, Daniela, et al.
Publicado: (2019)

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
por: Fathi, Anahita, et al.
Publicado: (2023)

Poxviral Ankyrin Proteins
por: Herbert, Michael H., et al.
Publicado: (2015)

MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination
por: Meyer zu Natrup, Christian, et al.
Publicado: (2023)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
por: Kupke, Alexandra, et al.
Publicado: (2022)

Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses
por: Riederer, Stephanie, et al.
Publicado: (2021)

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
por: Fathi, Anahita, et al.
Publicado: (2022)

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
por: Meyer zu Natrup, Christian, et al.
Publicado: (2022)

Poxviral Targeting of Interferon Regulatory Factor Activation
por: Lawler, Clara, et al.
Publicado: (2020)

Poxviral Strategies to Overcome Host Cell Apoptosis
por: Suraweera, Chathura D., et al.
Publicado: (2020)

Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1
por: Berthoud, Tamara K., et al.
Publicado: (2011)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years
por: Antrobus, Richard D., et al.
Publicado: (2012)

Origin of the poxviral membrane: A 50-year-old riddle
por: Moss, Bernard
Publicado: (2018)

Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects
por: Draper, Simon J., et al.
Publicado: (2013)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Poxviral ANKR/F-box Proteins: Substrate Adapters for Ubiquitylation and More
por: Ingham, Robert J., et al.
Publicado: (2022)

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise
por: Kubinski, Mareike, et al.
Publicado: (2020)

Obstetric Ultrasonography to Detect Fetal Abnormalities in a Mouse Model for Zika Virus Infection
por: Forster, Dominik, et al.
Publicado: (2020)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
por: Folegatti, Pedro M., et al.
Publicado: (2019)

T Cell Inactivation by Poxviral B22 Family Proteins Increases Viral Virulence
por: Alzhanova, Dina, et al.
Publicado: (2014)

Widespread Distribution and Evolution of Poxviral Entry-Fusion Complex Proteins in Giant Viruses
por: Kao, Sheng, et al.
Publicado: (2023)

Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
por: Lillie, Patrick J., et al.
Publicado: (2012)

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
por: Förster, Reinhold, et al.
Publicado: (2020)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice
por: Beicht, Jana, et al.
Publicado: (2023)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9umv765rio2kpdcvpjhfo8vnld